GF
REGN icon

GGM Financials’s Regeneron Pharmaceuticals REGN Stock Holding History

GGM Financials’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.4K Hold
159
– – 0.04% 120
2026
Q1 		$123K Sell
159
-105
-40% -$80.4K 0.06% 93
2025
Q4 		$204K Hold
264
– – 0.1% 66
2025
Q3 		$149K Buy
+264
New +$149K 0.07% 73
2024
Q4 		– Sell
-264
Closed -$278K – 59
2024
Q3 		$278K Hold
264
– – 0.24% 45
2024
Q2 		$277K Buy
+264
New +$256K 0.26% 44

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

GGM Financials's REGN Position: Q2 2026 in Review

GGM Financials held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 159 shares worth $99.4K. The position accounts for 0.04% of the portfolio, ranked #120.

GGM Financials first reported a position in REGN in Q2 2024 and has held it in 6 quarters since. The position peaked at $278K in Q3 2024. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • GGM Financials held 159 shares of Regeneron Pharmaceuticals worth $99.4K as of Q2 2026.
  • GGM Financials left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.04% of GGM Financials's portfolio in Q2 2026, its #120 holding.
  • GGM Financials first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • GGM Financials's Regeneron Pharmaceuticals position peaked at $278K in Q3 2024.
  • 334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GGM Financials's 13F filing for Q2 2026, filed 23 Jul 2026.